PharmAust Ltd
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II cli… Read more
PharmAust Ltd (ECQ) - Total Liabilities
Latest total liabilities as of June 2024: €896.61K EUR
Based on the latest financial reports, PharmAust Ltd (ECQ) has total liabilities worth €896.61K EUR as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PharmAust Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how PharmAust Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PharmAust Ltd Competitors by Total Liabilities
The table below lists competitors of PharmAust Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Capital & Regional Plc
PINK:CRPLF
|
USA | $253.90 Million |
|
Mobile Appliance Inc.
KQ:087260
|
Korea | ₩13.56 Billion |
|
Pinago Utama Tbk Pt
JK:PNGO
|
Indonesia | Rp513.71 Billion |
|
Anam Electroni
KO:008700
|
Korea | ₩105.07 Billion |
|
Atp Ticari Bilgisayar Agi ve Elektrik Guc Kaynaklari Uretim Pazarlama ve Ticaret
IS:ATATP
|
Turkey | TL633.82 Million |
|
DEVEX Resources Ltd
AU:DEV
|
Australia | AU$2.31 Million |
|
TRJNF
PINK:TRJNF
|
USA | $90.01 Million |
|
Exacompta Clairefontaine
PA:ALEXA
|
France | €436.16 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down PharmAust Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PharmAust Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PharmAust Ltd (2014–2024)
The table below shows the annual total liabilities of PharmAust Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €896.61K | -59.99% |
| 2023-06-30 | €2.24 Million | +0.33% |
| 2022-06-30 | €2.23 Million | +7.75% |
| 2021-06-30 | €2.07 Million | -6.62% |
| 2020-06-30 | €2.22 Million | +94.77% |
| 2019-06-30 | €1.14 Million | -6.55% |
| 2018-06-30 | €1.22 Million | -4.72% |
| 2017-06-30 | €1.28 Million | +3.73% |
| 2016-06-30 | €1.23 Million | +80.64% |
| 2015-06-30 | €683.22K | +53.37% |
| 2014-06-30 | €445.48K | -- |